Quick Answer
Cartesian Therapeutics, Inc. reported Cash and Equivalents of $125.14 million for fiscal year 2025.
Cartesian Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $125.14M | -41.1% |
| 2024 | $212.61M | +176.4% |
| 2023 | $76.91M | -27.7% |
| 2022 | $106.44M | -6.7% |
| 2021 | $114.06M | -17.8% |
| 2020 | $138.69M | +54.3% |
| 2019 | $89.89M | +140.3% |
| 2018 | $37.40M | -47.0% |
| 2017 | $70.62M | +20.4% |
| 2016 | $58.66M | +81.4% |
| 2015 | $32.34M | +94.9% |
| 2014 | $16.59M | +105.9% |
| 2013 | $8.06M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $143.38M | -34.6% | -10.6% |
| June 30, 2025 | $160.32M | +83.8% | -11.1% |
| March 31, 2025 | $180.43M | +74.5% | -15.1% |
| December 31, 2024 | $212.61M | +176.4% | -3.0% |
| September 30, 2024 | $219.20M | +175.4% | +151.3% |
| June 30, 2024 | $87.23M | -22.1% | -15.7% |
| March 31, 2024 | $103.42M | -17.9% | +34.5% |
| December 31, 2023 | $76.91M | -27.7% | -3.4% |
- Cartesian Therapeutics, Inc. showed a decrease of -41.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2025 period, Cartesian Therapeutics, Inc.’s cash and equivalents has grown by 1453.2% (from $8.06 million to $125.14 million).
- The most recent figure is from Cartesian Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: